Hospitals see minor financial improvement in May

After a brutal two months of significant revenue losses, hospitals saw a slight improvement in margins during May, according to the latest Flash Report from Kaufman Hall.

The improvement was in part due to financial help from the CARES Act, which contributed $50 billion to hospitals, as well as an increase in volume after elective surgeries resumed following a temporary pause as COVID-19 cases rose. May’s median hospital operating margin rose to 4% thanks to the funding relief. Without it, hospital margins were expected to be -8%. Compared to April, margins were up 100% in May.

Year over year, hospital margins are still down 13% and 6% below budget, according to the report. In April, year-over-year operating margins were down 282%.

Cases in the U.S. are still on the rise, with nearly  2.35 million cases reported in the nation and more than 121,000 deaths.

“The May results provide a glimmer of hope for our nation’s hospitals, but they also serve as a stark reminder of the long road ahead,” Jim Blake, managing director at Kaufman Hall and author of the report, said in a statement.

Hospital volumes improved in May, with adjusted discharges up 30% compared to April, but still down 27% compared to the same period last year and 26% below budget. Operating room minutes rose 92% from April to May, another result from non-emergency procedures resuming.

Actual revenues decreased further on a year-over-year basis, but adjust revenues showed slight year-over-year gains thanks to lower volumes. Compared to April, total gross revenue was up 29% from April, but down 14% compared to las tear.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.